Plasma Pharmacokinetics (PK) & Lung Penetration of Ceftolozane/Tazobactam in Participants With Pneumonia (MK-7625A-007)

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

February 5, 2015

Primary Completion Date

June 15, 2017

Study Completion Date

June 16, 2017

Conditions
Critically IllPneumonia
Interventions
DRUG

Ceftolozane/Tazobactam - Multiple Doses

"4-6 doses of ceftolozane/tazobactam every 8 hours as a 60-minute intravenous infusion as follows:~* Participants with CLCR \> 50 mL/min will receive 4-6 doses of 3 g ceftolozane/tazobactam every 8 hours~* Participants with CLCR 30 - 50 mL/min will receive 4-6 doses of 1.5 g ceftolozane/tazobactam every 8 hours~* Participants with CLCR 15 - 29 mL/min will receive 6 doses of 750 mg ceftolozane/tazobactam every 8 hours"

DRUG

Ceftolozane/Tazobactam - Single Dose

Single dose of ceftolozane/tazobactam, 3 g, as a 60-minute intravenous infusion

All Listed Sponsors
lead

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT02387372 - Plasma Pharmacokinetics (PK) & Lung Penetration of Ceftolozane/Tazobactam in Participants With Pneumonia (MK-7625A-007) | Biotech Hunter | Biotech Hunter